Edition:
India

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,234JPY
14 Aug 2020
Change (% chg)

¥32 (+0.52%)
Prev Close
¥6,202
Open
¥6,210
Day's High
¥6,244
Day's Low
¥6,191
Volume
692,500
Avg. Vol
1,330,844
52-wk High
¥7,183
52-wk Low
¥4,379

Latest Key Developments (Source: Significant Developments)

Shionogi & Co Ltd - Entered Into Agreement With Ping An Life Insurance Company Of China To Form Joint Venture
Monday, 27 Jul 2020 

July 27 (Reuters) - Shionogi & Co Ltd <4507.T>::SHIONOGI & CO LTD - ENTERED INTO AGREEMENT WITH PING AN LIFE INSURANCE COMPANY OF CHINA TO FORM JOINT VENTURE.  Full Article

Shionogi & Co Ltd - Notice Regarding Tetra Becoming A Wholly Owned Subsidiary Of Shionogi
Tuesday, 26 May 2020 

May 26 (Reuters) - Shionogi & Co Ltd <4507.T>::NOTICE REGARDING TETRA BECOMING A WHOLLY OWNED SUBSIDIARY OF SHIONOGI.SHIONOGI WILL HAVE ALL GLOBAL RIGHTS TO BPN14770 AND ALL TETRA COMPOUNDS AS RESULT OF ACQUISITION.IMPACT OF TETRA ACQUISITION TO HAVE LIMITED IMPACT ON FY2020/21 CONSOLIDATED EARNINGS FORECAST AT THIS TIME.  Full Article

Viiv Healthcare Receives CRL From FDA For Use Of Investigational Cabotegravir, Rilpivirine Long-Acting Regimen In HIV Treatment
Saturday, 21 Dec 2019 

Dec 21 (Reuters) - ViiV Healthcare::RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR USE OF INVESTIGATIONAL CABOTEGRAVIR, RILPIVIRINE LONG-ACTING REGIMEN IN HIV TREATMENT.NO REPORTED SAFETY ISSUES RELATED TO CMC; NO CHANGE TO SAFETY PROFILE OF PRODUCTS USED IN CLINICAL TRIALS TO DATE.REASONS GIVEN IN CRL RELATE TO CHEMISTRY MANUFACTURING AND CONTROLS.  Full Article

GSK Long-Acting HIV Injection Meets Goal In Late Stage Study
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV RESULTS POSITIVE FOR EVERY 2 MONTH INJECTION.GSK- PHASE III STUDY RESULTS OF INVESTIGATIONAL, LONG-ACTING, INJECTABLE HIV-TREATMENT TWO MONTHS REGIMEN ATLAS-2M STUDY MET ITS PRIMARY ENDPOINT.GLAXOSMITHKLINE PLC - DETAILED RESULTS FROM ATLAS-2M STUDY WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING.  Full Article

Shionogi & Co: Bought Back 7.35 Million Shares For About 50 Billion Yen Through Dec 18
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Japan's Shionogi & Co Ltd <4507.T>::BOUGHT BACK 7.35 MILLION SHARES FOR ABOUT 50 BILLION YEN THROUGH DEC 18.  Full Article

Tetra Discovery Partners And Shionogi & Co., Ltd. Collaborate On Bpn14770 Development And Commercialization
Wednesday, 19 Dec 2018 

Dec 18 (Reuters) - Shionogi & Co Ltd <4507.T>::TETRA DISCOVERY PARTNERS AND SHIONOGI & CO., LTD. COLLABORATE ON BPN14770 DEVELOPMENT AND COMMERCIALIZATION.SHIONOGI & CO LTD - DEAL VALUED AT POTENTIAL $160 MILLION PLUS ROYALTIES, INCLUDING $5 MILLION IN UPFRONT PAYMENTS AND $35 MILLION IN EQUITY INVESTMENT.SHIONOGI & CO LTD - SHIONOGI GAINS REGIONAL LICENSE TO ALZHEIMER'S DRUG CANDIDATE FOR JAPAN, KOREA AND TAIWAN.SHIONOGI & CO - TETRA TO ALSO BE ELIGIBLE TO GET UP TO ADDITIONAL $120 MILLION IN DEVELOPMENT, COMMERCIALIZATION MILESTONES, AS WELL AS ROYALTIES ON SALES.SHIONOGI & CO LTD - FURTHER FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED..SHIONOGI & CO - IN EXCHANGE FOR GRANTING CO DEVELOPMENT RIGHTS TO BPN14770 IN JAPAN, TAIWAN, KOREA, TETRA RECEIVED $40 MILLION IN COMBINED UPFRONT FUNDING.  Full Article

Shionogi & Co Bought Back Own Shares For 10.22 Billion Yen In November
Friday, 14 Dec 2018 

Shionogi & Co Ltd <4507.T>::BOUGHT BACK OWN SHARES FOR 10.22 BILLION YEN IN NOVEMBER.  Full Article

SHIONOGI increases voting power in UMN Pharma to 20.3 pct
Wednesday, 31 Oct 2018 

Oct 31(Reuters) - UMN Pharma Inc <4585.T>:Says SHIONOGI & CO LTD <<<4507.T>>> increases voting power in UMN Pharma to 20.3 percent from 4.7 percent, effective Oct. 31 .  Full Article

R&I affirms Shionogi's rating at "A+" and changes outlook to positive -R&I
Friday, 26 Oct 2018 

Oct 26(Reuters) - Shionogi & Co Ltd <4507.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook changes to positive from stable -R&I.  Full Article

Shionogi announces FDA approval of Baloxavir Marboxil for treatment of acute, uncomplicated influenza
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Shionogi & Co Ltd <4507.T>:Says the company announced today that, after completing a priority review, the United States Food and Drug Administration (FDA) has approved XOFLUZATM(baloxavir marboxil) for the treatment of acute, uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.  Full Article

Photo

U.S. FDA approves GSK's HIV drug for patients with limited options

The U.S. Food and Drug Administration on Thursday approved GlaxoSmithKline Plc's HIV drug, Rukobia, to treat adult patients who have run out of treatment options.